BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 33655393)

  • 21. Comparison of single copy gene‑based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19‑directed CAR T cells in treated patients.
    Schubert ML; Berger C; Kunz A; Schmitt A; Badbaran A; Neuber B; Zeschke S; Wang L; Riecken K; Hückelhoven-Krauss A; Müller I; Müller-Tidow C; Dreger P; Kröger N; Ayuk FA; Schmitt M; Fehse B
    Int J Oncol; 2022 May; 60(5):. PubMed ID: 35294040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells in Humans.
    Liu C; Ayyar VS; Zheng X; Chen W; Zheng S; Mody H; Wang W; Heald D; Singh AP; Cao Y
    Clin Pharmacol Ther; 2021 Mar; 109(3):716-727. PubMed ID: 33002189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies.
    Mamonkin M; Mukherjee M; Srinivasan M; Sharma S; Gomes-Silva D; Mo F; Krenciute G; Orange JS; Brenner MK
    Cancer Immunol Res; 2018 Jan; 6(1):47-58. PubMed ID: 29079655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.
    Nakajima M; Sakoda Y; Adachi K; Nagano H; Tamada K
    Cancer Sci; 2019 Oct; 110(10):3079-3088. PubMed ID: 31432594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells.
    Reichman A; Kunz A; Joedicke JJ; Höpken UE; Keib A; Neuber B; Sedloev D; Wang L; Jiang G; Hückelhoven-Krauss A; Eberhardt F; Müller-Tidow C; Wermke M; Rehm A; Schmitt M; Schmitt A
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer.
    Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W
    Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
    Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC
    Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.
    Owens GL; Sheard VE; Kalaitsidou M; Blount D; Lad Y; Cheadle EJ; Edmondson RJ; Kooner G; Gilham DE; Harrop R
    J Immunother; 2018 Apr; 41(3):130-140. PubMed ID: 29239915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generation of CAR-T Cells for Cancer Immunotherapy.
    Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
    Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma.
    Wu X; Luo H; Shi B; Di S; Sun R; Su J; Liu Y; Li H; Jiang H; Li Z
    Mol Ther; 2019 Aug; 27(8):1483-1494. PubMed ID: 31078430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy.
    Hajari Taheri F; Hassani M; Sharifzadeh Z; Behdani M; Arashkia A; Abolhassani M
    IUBMB Life; 2019 Sep; 71(9):1259-1267. PubMed ID: 30724452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization.
    Leung WH; Gay J; Martin U; Garrett TE; Horton HM; Certo MT; Blazar BR; Morgan RA; Gregory PD; Jarjour J; Astrakhan A
    JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31039141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.
    Balakrishnan A; Rajan A; Salter AI; Kosasih PL; Wu Q; Voutsinas J; Jensen MC; Plückthun A; Riddell SR
    Clin Cancer Res; 2019 Dec; 25(24):7506-7516. PubMed ID: 31548346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Real-Time Quantitative PCR Targeting the Viral Vector for the Monitoring of Patients Treated with Axicabtagene Ciloleucel.
    Baras A; Bocket L; Beauvais D; Hallaert C; Varlet P; Yakoub-Agha I; Hober D; Alidjinou EK
    J Mol Diagn; 2021 Apr; 23(4):447-454. PubMed ID: 33385585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunophenotypic Analysis of CAR-T Cells.
    de Azevedo JTC; Mizukami A; Moço PD; Malmegrim KCR
    Methods Mol Biol; 2020; 2086():195-201. PubMed ID: 31707677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of CAR T cell expansion and cytotoxic potential during Ex Vivo manufacturing using image-based cytometry.
    Maldini CR; Love AC; Tosh KW; Chan LL; Gayout K; Smith T; Riley JL
    J Immunol Methods; 2020; 484-485():112830. PubMed ID: 32745474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An immunoproteomic approach to characterize the CAR interactome and signalosome.
    Ramello MC; Benzaïd I; Kuenzi BM; Lienlaf-Moreno M; Kandell WM; Santiago DN; Pabón-Saldaña M; Darville L; Fang B; Rix U; Yoder S; Berglund A; Koomen JM; Haura EB; Abate-Daga D
    Sci Signal; 2019 Feb; 12(568):. PubMed ID: 30755478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
    Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
    Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A transgene-encoded truncated human epidermal growth factor receptor for depletion of anti- B-cell maturation antigen CAR-T cells.
    Wang Q; He F; He W; Huang Y; Zeng J; Zi F; Zheng J; Fei Y; Xu J; Song Y; Ye X; Lai R; Ye L; Zhu B
    Cell Immunol; 2021 May; 363():104342. PubMed ID: 33765541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-Throughput Flow Cytometric Method for the Simultaneous Measurement of CAR-T Cell Characterization and Cytotoxicity against Solid Tumor Cell Lines.
    Martinez EM; Klebanoff SD; Secrest S; Romain G; Haile ST; Emtage PCR; Gilbert AE
    SLAS Discov; 2018 Aug; 23(7):603-612. PubMed ID: 29634393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.